Atai Life Sciences N.V. (ATAI)
| Bid | 1.47 |
| Market Cap | 293.7M |
| Revenue (ttm) | 308K |
| Net Income (ttm) | -149.27M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -1.58 |
| Forward PE | -1.89 |
| Analyst | Buy |
| Ask | 1.57 |
| Volume | 858,051 |
| Avg. Volume (20D) | 2,844,072 |
| Open | 1.49 |
| Previous Close | 1.50 |
| Day's Range | 1.45 - 1.53 |
| 52-Week Range | 1.03 - 2.56 |
| Beta | 1.25 |
About ATAI
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modul...
Analyst Forecast
According to 3 analyst ratings, the average rating for ATAI stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 614.29% from the latest price.
Stock Forecasts
1 month ago · proactiveinvestors.com
atai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMIatai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical reado...
1 month ago · proactiveinvestors.com
atai Life Sciences entering catalyst-rich period with high-potential data readouts in 2025 and 2026atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourt...
1 month ago · proactiveinvestors.com
atai Life Sciences prepares for data readouts from key clinical trials, extends operational runwayatai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as it strengthened its financial position. The company successfully dose...
1 month ago · proactiveinvestors.com
atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trialatai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company's oral transmucosal film formulation of DMT applied to the...
1 month ago · proactiveinvestors.com
atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollmentatai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech's Phase 2b trial evaluating BPL-003 in treatment-resistant depression (TRD), with topl...
2 months ago · proactiveinvestors.com
atai Life Sciences completes public offering, raising $63.25Matai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter's option to purchase additional shares for gross proceeds of approximately $63.2...
2 months ago · proactiveinvestors.com
atai Life Sciences announces pricing of $55M public offering of sharesatai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million. The underwr...